SinoBiomed Inc. (“SinoBiomedÂ) is a leading Chinese developer of genetically engineered recombinant protein drugs and vaccines.
SinoBiomed has announced that the United States Patent and Trademark office has granted a patent for the malaria vaccine PfCP2.9 to which SinoBiomed has exclusive rights to develop, manufactureÂ and sell through its 82 percent owned subsidiary, Shanghai Wanxing Bio-pharmaceuticals Co. Ltd.
Patent number 7,101,556 B2, dated September 5, 2006, has been assigned to the Second Military Medical University (SMMU) of Shanghai China. “The granting of this US patent enables SinoBiomed to
proceed with the vaccine development with full confidence in its potential for commercial development for the global market,” said Company President and CEO Banjun Yang.
The patent holder was granted the right to exclude others from making, using, offering for sale, or selling the invention throughout the United States with 20 years protection term from the dateÂ on which the earliest application was filed (February 1, 2002).